Northside Capital Management LLC Raises Holdings in Thermo Fisher Scientific Inc. $TMO

Northside Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,741 shares of the medical research company’s stock after acquiring an additional 9,519 shares during the period. Thermo Fisher Scientific makes up approximately 1.3% of Northside Capital Management LLC’s portfolio, making the stock its 20th biggest holding. Northside Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $16,415,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID grew its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the period. Allied Private Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $26,000. High Note Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. Finally, JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at approximately $28,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher completed Olink Explore HT proteomic analysis of approximately 5,500 samples for The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative. Making the data available to researchers could strengthen adoption of Thermo Fisher’s proteomics platform and support future precision-medicine demand. Thermo Fisher collaborates with The Michael J. Fox Foundation
• Positive Sentiment: A market report projects the non-viral transfection reagents market will grow from $0.89 billion in 2026 to $2.01 billion by 2035, a 9.5% compound annual growth rate. Thermo Fisher’s participation in this market gives investors another potential source of long-term life-sciences growth, though the report does not quantify the company’s expected share. Non-Viral Transfection Reagents Market Report
• Positive Sentiment: Thermo Fisher is targeting 15% to 20% customer-base growth in India over the next five years, supported by expanding biopharmaceutical research and manufacturing. The plan highlights a potentially attractive international growth opportunity for its instruments, services and bioproduction businesses. Thermo Fisher India customer growth
• Positive Sentiment: Recent coverage also highlighted FDA clearance for Thermo Fisher’s multiple myeloma testing platform, potentially broadening its clinical-diagnostics and precision-medicine opportunities among laboratories, hospitals and pharmaceutical companies. Thermo Fisher multiple myeloma platform
• Neutral Sentiment: Coverage of a new vitiligo registry suggests potential benefits for dermatology research and related laboratory workflows, but no specific revenue contribution or commercial agreement was disclosed, limiting the near-term stock impact. New vitiligo registry
• Neutral Sentiment: Articles comparing Thermo Fisher with Danaher, Abbott and Azenta focus on valuation and exposure to a recovery in pharmaceutical and biotechnology research spending rather than announcing new company fundamentals. Thermo Fisher versus Danaher
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares in transactions conducted under pre-arranged Rule 10b5-1 plans. The planned nature reduces the significance, but insider selling can create modest short-term pressure on investor sentiment. Thermo Fisher insider trading filing

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 26,553 shares of company stock valued at $15,343,589. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $604.18 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market cap of $223.40 billion, a PE ratio of 32.50, a P/E/G ratio of 2.44 and a beta of 0.85. The firm has a 50 day simple moving average of $522.21 and a 200-day simple moving average of $509.48. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. Piper Sandler upped their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Evercore set a $570.00 price target on Thermo Fisher Scientific in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.